| Literature DB >> 31007939 |
Siddhartha G Kapnadak1, Kathleen J Ramos1, Andrea M Lopriore2, Christopher H Goss1,3, Moira L Aitken1.
Abstract
BACKGROUND: Cystic fibrosis (CF) is a disease in which nutritional barriers are diverse and common, with malnutrition greatly influencing pulmonary trajectory and overall outcomes. Despite this, the most effective methods to optimize CF nutrition are unknown, and literature describing patients' perspectives on their specific nutritional needs is lacking, particularly in the modern era of CF care. This study aimed to identify the most important nutritional needs and desired health-improvement resources in a contemporary adult CF cohort.Entities:
Keywords: Cystic fibrosis; body composition; body mass index; complications; malnutrition; nutrition assessment; nutrition therapy; obesity
Year: 2019 PMID: 31007939 PMCID: PMC6474380 DOI: 10.1186/s40795-018-0266-3
Source DB: PubMed Journal: BMC Nutr ISSN: 2055-0928
Patient Characteristics by Cystic Fibrosis Transmembrane Regulator Mutation Status
| All Eligible Patients | CFTR Mutation Class I-III | CFTR Mutation Class IV-V | |||||
|---|---|---|---|---|---|---|---|
| Variable | Observed | N | Observed | N | Observed | N | |
| Age – mean (SD), years | 32.3 (11.4) | 66 | 30.4 (8.8) | 54 | 40.8 (17.2) | 12 | 0.0637 |
| Male gender | 32 (48.5) | 66 | 27 (50.0) | 54 | 5 (41.7) | 12 | 0.601 |
| Medicaid Insurance | 23 (35.4) | 65 | 17 (32.1) | 53 | 6 (50.0) | 12 | 0.241 |
| CFTR mutation status | 66 | ||||||
| Homozygous Class I-III | 54 (81.8) | ||||||
| Heterozygous Class I-III | 12 (18.2) | ||||||
| Homozygous Class IV-V | 0 (0) | ||||||
| FEV1 - % predicted (SD) | 59.3 (23.3) | 66 | 57.3 (22.7) | 54 | 68.3 (24.9) | 12 | 0.178 |
| Weight – mean (SD), kg | 66.1 (14.6) | 66 | 63.9 (11.9) | 54 | 76.0 (21.2) | 12 | 0.079 |
| BMI – mean (SD), kg/m2 | 23.4 (4.3) | 66 | 22.8 (3.5) | 54 | 26.2 (6.4) | 12 | 0.099 |
| BMI < 18.5 | 9 (13.6) | 66 | 7 (13.0) | 54 | 2 (16.7) | 12 | 0.663b |
| BMI 18.5–24.99 | 38 (57.6) | 66 | 34 (63.0) | 54 | 4 (33.3) | 12 | 0.104b |
| BMI 25–29.99 | 13 (19.7) | 66 | 11 (20.4) | 54 | 2 (16.7) | 12 | 1.000b |
| BMI ≥ 30 | 6 (9.1) | 66 | 2 (3.7) | 54 | 4 (33.3) | 12 |
|
| BMI meeting CFF goala | 38 (57.6) | 66 | 29 (53.7) | 54 | 9 (75.0) | 12 | 0.177b |
| CF-related diabetes on insulin | 15 (23.1) | 65 | 14 (26.4) | 53 | 1 (8.3) | 12 | 0.267b |
| CF-related PI on enzymes | 58 (89.2) | 65 | 52 (98.1) | 53 | 6 (50.0) | 12 |
|
| Prednisone use (at time of survey) | 5 (7.7) | 65 | 5 (9.4) | 53 | 0 (0) | 12 | 0.575b |
| PEG tube in place | 2 (3.1) | 65 | 1 (1.9) | 53 | 1 (8.3) | 12 | 0.338b |
| Nutritional supplement use | 32 (49.2) | 65 | 26 (49.1) | 53 | 6 (50.0) | 12 | 0.953 |
Data are presented as No. (%) unless indicated otherwise. Certain background clinical data were not recorded and were thus unavailable for one individual
aCFF goal for weight is BMI ≥22 kg/m2 for females, and ≥ 23 kg/m2 for males
b= Fisher’s exact test
CF cystic fibrosis, SD standard deviation, CFTR cystic fibrosis transmembrane conductance regulator gene, FEV1 forced expiratory volume in one second, BMI body mass index, CFF Cystic Fibrosis Foundation, PI pancreatic insufficiency, PEG percutaneous endoscopic gastrostomy
Fig. 1Primary nutrition concerns. a In the entire cohort; b) By BMI (in kg/ m2); c) By gender; d) By insurance status, (BMI = Body mass index)
Fig. 2Preferred health-improvement resources. a In entire cohort; b) By BMI (in kg/m2); c) By gender; d) By insurance status, (BMI = Body mass index, CF = Cystic fibrosis)